FOXA1 as a therapeutic target for breast cancer

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Gene expression profiling studies have classified breast cancer into five intrinsic subtypes with distinct prognostic significance: luminal type A, luminal type B, normal-like, HER-2-positive and basal type. These studies have also uncovered novel diagnostic markers and molecular targets. FOXA1, a winged-helix transcription factor belonging to the forkhead family, is one among them as it is expressed predominantly in luminal type A breast cancer, which is characterized by the presence of estrogen receptor-α (ERα) with favorable prognosis. FOXA1 is a 'pioneer' factor that binds to chromatinized DNA, opens the chromatin and enhances binding of ERα to its target genes. It is essential for the expression of ∼ 50% of ERα:estrogen-regulated genes. Thus, a network comprising FOXA1, ERα and estrogen constitutes a major proliferation and survival signal for luminal type A breast cancer. However, by controlling differentiation and by regulating the expression of cell cycle inhibitor p27kip1 and the cell adhesion molecule E-cadherin, FOXA1 may prevent metastatic progression of luminal type A breast cancer. This article reviews possible roles of FOXA family transcription factors in breast cancer initiation, hormone dependency and speculates on the potential of FOXA1 as a therapeutic target.

Original languageEnglish
Pages (from-to)507-514
Number of pages8
JournalExpert Opinion on Therapeutic Targets
Volume11
Issue number4
DOIs
StatePublished - Apr 2007

Fingerprint

Estrogen Receptors
Breast Neoplasms
Estrogens
Winged-Helix Transcription Factors
Genes
Cell Adhesion Molecules
Cadherins
Therapeutics
Gene expression
Molecular Pathology
Chromatin
Gene Expression Profiling
Transcription Factors
Cells
Hormones
Cell Cycle
DNA

Keywords

  • Breast cancer
  • Estrogen receptor
  • FOXA1
  • Luminal type A

ASJC Scopus subject areas

  • Molecular Medicine
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

FOXA1 as a therapeutic target for breast cancer. / Nakshatri, Harikrishna; Badve, Sunil.

In: Expert Opinion on Therapeutic Targets, Vol. 11, No. 4, 04.2007, p. 507-514.

Research output: Contribution to journalArticle

@article{c2b93fb253f04eb0b57b402e3f7f3a4c,
title = "FOXA1 as a therapeutic target for breast cancer",
abstract = "Gene expression profiling studies have classified breast cancer into five intrinsic subtypes with distinct prognostic significance: luminal type A, luminal type B, normal-like, HER-2-positive and basal type. These studies have also uncovered novel diagnostic markers and molecular targets. FOXA1, a winged-helix transcription factor belonging to the forkhead family, is one among them as it is expressed predominantly in luminal type A breast cancer, which is characterized by the presence of estrogen receptor-α (ERα) with favorable prognosis. FOXA1 is a 'pioneer' factor that binds to chromatinized DNA, opens the chromatin and enhances binding of ERα to its target genes. It is essential for the expression of ∼ 50{\%} of ERα:estrogen-regulated genes. Thus, a network comprising FOXA1, ERα and estrogen constitutes a major proliferation and survival signal for luminal type A breast cancer. However, by controlling differentiation and by regulating the expression of cell cycle inhibitor p27kip1 and the cell adhesion molecule E-cadherin, FOXA1 may prevent metastatic progression of luminal type A breast cancer. This article reviews possible roles of FOXA family transcription factors in breast cancer initiation, hormone dependency and speculates on the potential of FOXA1 as a therapeutic target.",
keywords = "Breast cancer, Estrogen receptor, FOXA1, Luminal type A",
author = "Harikrishna Nakshatri and Sunil Badve",
year = "2007",
month = "4",
doi = "10.1517/14728222.11.4.507",
language = "English",
volume = "11",
pages = "507--514",
journal = "Expert Opinion on Therapeutic Targets",
issn = "1472-8222",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - FOXA1 as a therapeutic target for breast cancer

AU - Nakshatri, Harikrishna

AU - Badve, Sunil

PY - 2007/4

Y1 - 2007/4

N2 - Gene expression profiling studies have classified breast cancer into five intrinsic subtypes with distinct prognostic significance: luminal type A, luminal type B, normal-like, HER-2-positive and basal type. These studies have also uncovered novel diagnostic markers and molecular targets. FOXA1, a winged-helix transcription factor belonging to the forkhead family, is one among them as it is expressed predominantly in luminal type A breast cancer, which is characterized by the presence of estrogen receptor-α (ERα) with favorable prognosis. FOXA1 is a 'pioneer' factor that binds to chromatinized DNA, opens the chromatin and enhances binding of ERα to its target genes. It is essential for the expression of ∼ 50% of ERα:estrogen-regulated genes. Thus, a network comprising FOXA1, ERα and estrogen constitutes a major proliferation and survival signal for luminal type A breast cancer. However, by controlling differentiation and by regulating the expression of cell cycle inhibitor p27kip1 and the cell adhesion molecule E-cadherin, FOXA1 may prevent metastatic progression of luminal type A breast cancer. This article reviews possible roles of FOXA family transcription factors in breast cancer initiation, hormone dependency and speculates on the potential of FOXA1 as a therapeutic target.

AB - Gene expression profiling studies have classified breast cancer into five intrinsic subtypes with distinct prognostic significance: luminal type A, luminal type B, normal-like, HER-2-positive and basal type. These studies have also uncovered novel diagnostic markers and molecular targets. FOXA1, a winged-helix transcription factor belonging to the forkhead family, is one among them as it is expressed predominantly in luminal type A breast cancer, which is characterized by the presence of estrogen receptor-α (ERα) with favorable prognosis. FOXA1 is a 'pioneer' factor that binds to chromatinized DNA, opens the chromatin and enhances binding of ERα to its target genes. It is essential for the expression of ∼ 50% of ERα:estrogen-regulated genes. Thus, a network comprising FOXA1, ERα and estrogen constitutes a major proliferation and survival signal for luminal type A breast cancer. However, by controlling differentiation and by regulating the expression of cell cycle inhibitor p27kip1 and the cell adhesion molecule E-cadherin, FOXA1 may prevent metastatic progression of luminal type A breast cancer. This article reviews possible roles of FOXA family transcription factors in breast cancer initiation, hormone dependency and speculates on the potential of FOXA1 as a therapeutic target.

KW - Breast cancer

KW - Estrogen receptor

KW - FOXA1

KW - Luminal type A

UR - http://www.scopus.com/inward/record.url?scp=33947630304&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947630304&partnerID=8YFLogxK

U2 - 10.1517/14728222.11.4.507

DO - 10.1517/14728222.11.4.507

M3 - Article

C2 - 17373880

AN - SCOPUS:33947630304

VL - 11

SP - 507

EP - 514

JO - Expert Opinion on Therapeutic Targets

JF - Expert Opinion on Therapeutic Targets

SN - 1472-8222

IS - 4

ER -